Previous 10 | Next 10 |
home / stock / gild / gild articles
Morgan Stanley initiates Arcellx Inc (NASDAQ:ACLX), noting a differentiated CAR-T platform for blood cancer backed by an established...
Gilead Sciences Inc (NASDAQ:GILD) and Merck & Co Inc (NYSE:MRK) released results from the Phase 2 clinical study evaluating the ...
Biogen Inc (NASDAQ:BIIB) released interim 6-month biomarker data from the initial 29 participants in the open-label RESPOND study. The Ph...
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 4.93% on an annualized basis producing an average annual return...
Gilead Sciences Inc (NASDAQ:GILD) said it paused tumor study enrollment. The Food and Drug Administration (FDA) subsequently requested a partial...
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have hig...
Monday, Gilead Sciences Inc (NASDAQ:GILD) agreed to acquire CymaBay Therapeutics Inc (NASDAQ:CBAY) for $32.50 per share i...
U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday. The Dow traded up 0.48% to 38,856.99 ...
Gilead Sciences (NASDAQ:GILD) has announced an acquisition of CymaBay Therapeutics (NASDAQ:CBAY) that is expected to be completed in Q1 of 2024. Un...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...